Quantum Genomics SA
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
10
Active:0
Completed:8
Trial Phases
3 Phases
Phase 1:4
Phase 2:4
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (40.0%)Phase 2
4 (40.0%)Phase 3
2 (20.0%)Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)
Phase 3
Terminated
- Conditions
- Hypertension (HTN)
- Interventions
- Drug: Firibastat (QGC001) Period 1
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Quantum Genomics SA
- Target Recruit Count
- 419
- Registration Number
- NCT04857840
- Locations
- 🇺🇸
Manassas Clinical Research Center, Manassas, Virginia, United States
🇨🇦Canadian Phase Onward, Toronto, Ontario, Canada
Pharmacokinetics in End Stage Renal Disease Patients
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Quantum Genomics SA
- Target Recruit Count
- 28
- Registration Number
- NCT04792333
- Locations
- 🇫🇷
Eurofins Optimed, Gières, France
Firibastat in Treatment-resistant Hypertension
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Quantum Genomics SA
- Target Recruit Count
- 515
- Registration Number
- NCT04277884
- Locations
- 🇺🇸
Central Alabama Research, Birmingham, Alabama, United States
🇺🇸Marvel Clinical Research, Huntington Beach, California, United States
🇺🇸Orange County Research Center, Tustin, California, United States
Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Quantum Genomics SA
- Target Recruit Count
- 295
- Registration Number
- NCT03715998
- Locations
- 🇫🇷
Groupe Hospitalier Pitie-Salpêtrière - Institut de Cardiologie, Paris, France
🇩🇪UKSH Kiel, Kiel, Germany
🇭🇺Central Hospital of Hungarian Army, Budapest, Hungary
Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet Formulations
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2019-06-18
- Lead Sponsor
- Quantum Genomics SA
- Target Recruit Count
- 12
- Registration Number
- NCT03714685
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
- Prev
- 1
- 2
- Next
News
No news found